From Promise to Proof
Join us in our travel back to the beginnings of what is clinically proven now: HighVolumeHDF.
Our desire to achieve the best possible outcomes for all dialysis patients has fuelled more than a thirty year commitment to developing an innovative high volume online Haemodiafiltration (HDF) product line. This passion rests on the belief that high volume online HDF therapy is the most effective dialysis treatment modality for all patients - a conviction that is now widely shared across the scientific community and backed by convincing clinical evidence.1
Most recently, evidence of this has been documented in the Catalonian ESHOL Study published in JASN (Journal of the American Society of Nephrology) which is a prospective, randomized, clinical trial on more than 900 patients with renal failure from 27 different Catalan centers.1
Our passion for HDF began in 1983 when we developed our first conventional HDF product with solution bags. This was followed in 1988 by the A2008 Online HDF product - our first system for online preparation of substitution fluid - and then by the 4008 ONLINEplus in 1998. Continued research and innovation led to the development of the 5008 Therapy System , which was first released in 2005 complemented by the 5008 CorDiax & 5008S CorDiax systems in Europe in 2012. The CorDiax product line perfectly supports the application of high volume online HDF therapy, which achieves high substitution volumes that result in more effective elimination of middle molecules - thereby more closely reflecting the elimination profile of the healthy kidney.
- Maduell F, Moreso F, Pons M, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013;24: 487-97.